The abstract is read at the publisher; the summary is JClub's.
In resected lung adenocarcinoma, TP53 and KRAS mutations predict worse stage I overall survival (HR 2.49 and 1.57), while stage I EGFR mutations predict better outcomes (HR 0.59).
- Why it matters: Gene alterations may be integrated into the tenth edition TNM framework, but their stage-specific prognostic value and potential to refine staging needed validation.
- What they did: From 2008–2021, 5839 resected patients were analyzed for TP53, EGFR (L858R/exon 19 deletion), KRAS (codons 12/13/61), and ALK fusions; Kaplan-Meier and Cox models tested stage-specific and independent effects.
- The result: Stage IA TP53- or KRAS-mutated disease showed overall survival comparable to stage IB, and stage III–IV ALK fusion-positive disease showed overall survival comparable to stage II, supporting upstaging/downstaging potential.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.